Peter Mørch Eriksen was appointed CEO of BioPorto in July 2013. Peter Mørch Eriksen has more than 15 years of experience within medtech/life science in Denmark and abroad. Prior to joining BioPorto, Peter Mørch Eriksen was CEO of Sense A/S and before this, he held positions as Vice President of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management. In addition to being CEO of BioPorto, Peter Mørch Eriksen chairs the board of MTIC, is a board member at Nervex A/S, member of Lund University Advisory Board, and Director of PMEconsult ApS. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.
Ole Larsen was appointed CFO of BioPorto in June 2018. Ole Larsen brings comprehensive industrial and financial knowledge to BioPorto as an experienced executive in international health care and media companies. Most recently from Bavarian Nordic A/S, a NASDAQ-listed Danish biotechnology company focused on cancer immunotherapies and vaccines for infectious diseases. Since 2008, Ole Larsen served as Executive Vice President and CFO and was responsible for Finance, IR and IT. Prior to this, Ole Larsen held CFO positions at two of the largest Danish and Nordic media groups, Nordisk Film and Berlingske Tidende. Ole Larsen holds a MSc in Economics from Copenhagen Business School.
Jan Kuhlmann Andersen was appointed COO of BioPorto in August 2016. Jan Kuhlmann Andersen is a very experienced executive having worked with sales within the life sciences area, mostly in US-owned companies such as FMC, Cambrex, Fisher Scientific and Thermo Fisher Scientific since 1995. From 2007 and until joining BioPorto, Jan Kuhlmann Andersen was Vice President, sales & marketing, in the Animal Health & Nutrition division in Chr. Hansen A/S. Jan Kuhlmann Andersen holds a PhD in immunology and a MSc in Biology, both from the University of Copenhagen. Jan Kuhlmann Andersen also serves as the Chairman of Cytovac A/S and was previously board member of Noscomed Medical Supply A/S, the French life science company Cell Made and of BioPorto A/S from 2015 to 2016.
Amy Winslow was appointed President of BioPorto Diagnostics, Inc. in April 2019. She is an experienced diagnostics executive, who most recently served as President and CEO of Magellan Diagnostics, a Boston-based point-of-care diagnostics company. While at Magellan, Amy Winslow lead the company’s restructuring for growth, increased profitability, built a dedicated commercial team, and ultimately ran a successful sale of the company to Meridian Bioscience, Inc. Prior to Magellan, among other roles, Amy Winslow served as VP Marketing for Athena Diagnostics, a neurodiagnostic specialty laboratory testing business that was later acquired by Quest Diagnostics. Amy Winslow has an MBA from Harvard Business School and a BA in Biology from Brown University.
Christopher Bird was appointed Chief Medical Officer of BioPorto in August 2019. Christopher Bird has an impressive scientific background and has delivered very strong results in business development, finance, sales, and marketing, and most recently as Head of Medical and Scientific Affairs at Roche Diagnostics Corp., where he headed the North American Medical / Scientific organization and strategy with responsibility for all clinical education, study management and field support during his 10 year tenure. Chris has a BA in physiology from Brigham Young University, a MA in biochemistry and molecular biology from University of California Los Angeles, and a DPhil in molecular immunology from Oxford University as an Abraham Scholar.
MBA from INSEAD and PhD and MSc from the Technical University of Denmark
Chairman and Board member since 2013
Thomas Magnussen is Chairman and co-founder and partner in QuantumWise A/S and Zylinc A/S respectively as well as an entrepreneur in the high-tech space, engaging in start-up companies with global business scope. Thomas Magnussen has experience in commercialization strategies and from industries including nanotechnology, ICT and medtech.
DIEUs top management education, VL and banking education
Board member since 2013
Torben A. Nielsen has for more than 25 years held senior positions in the financial sector. From 1998 to 2008 he was member of the executive management in Sydbank A/S responsible for asset management, capital markets, treasury, foreign and several other business areas, and from 2008 to 2012 he was the CEO of BankInvest A/S. Concurrently, he has held several national and international board positions, including at NASDAQ OMX. Of a total of 30 years in the financial sector, of which 5 years in New York and London, Torben A. Nielsen built and managed businesses at home and abroad in all relevant commercial business areas in the financial sector and has been involved in and responsible for several mergers and acquisitions.
MSc and PhD in pharmacology from the University of Copenhagen.
Board member since 2017.
Kirsten Aarup Drejer is co-founder of Symphogen A/S, a biopharmaceutical company focused on the innovative therapeutic utilization of antibodies. In the period from 2000 until 2016, Kirsten Aarup Drejer was CEO of Symphogen A/S. Before this, Kirsten Aarup Drejer held a number of scientific and managerial positions within Novo Nordisk A/S. Kirsten Aarup Drejer is a member of the board of directors of Symphogen A/S and the Danish Growth Fund and has previously been a member of the board of directors of, among others, Danisco A/S. Kirsten Aarup Drejer is a member of numerous advisory boards at the University of Copenhagen and the Copenhagen Business School. Kirsten Aarup Drejer won the prize of ”BiotechBuilder of the Year” in 2003 and ”Entrepreneur of the Year, Biotech” in 2007.
CPA, Massachusetts (US) and CA from Institute of chartered Accountants, Scotland
Board member since 2019
Christopher Lindop was previously a partner with Arthur Andersen and E&Y and has held numerous positions as Chief Financial Officer (CFO) in companies such as Inverness Medical Ltd., Haemonetics Corporation Ltd. (HAE) and since 2017 at Quotient Limited (QTNT). He has considerable experience in management of US listed health care and diagnostic companies and within finance and reporting, corporate governance, mergers & acquisitions, funding and strategy development and execution.
Ph.D. (neuroscience) and MD cum laude from Yale University, Connecticut
Board member since 2019
Michael S. Singer is Chief Scientific Officer (CSO) and co-founder of Cartesian Therapeutics, Inc., a US biotech company. Before this he was co-founder and CSO of Topokine Therapeutics, Inc., and Health Honors Corporation. His experience also includes leading Translational Medicine at Novartis Institutes for Biomedical Research as a director and being a physician and surgeon. Michael S. Singer possess significant experience and skills in designing and executing pre-clinical and clinical development processes in biotech and health care companies.